|
|
|
| MILRINONE | ||
|
PRODUCT IDENTIFICATION |
||
| CAS NO. | 78415-72-2 |
|
| EINECS NO. | 278-903-6 | |
| FORMULA | C12H9N3O | |
| MOL WT. | 211.22 | |
|
H.S. CODE |
||
|
TOXICITY |
||
| SMILES |
|
|
| SYNONYMS | 1,6-Dihydro-2-methyl-6-oxo-(3,4'-bipyridine)-5-carbonitrile; | |
|
CLASSIFICATION |
||
|
PHYSICAL AND CHEMICAL PROPERTIES |
||
| PHYSICAL STATE | yellow crystalline powder | |
| MELTING POINT | 300 C | |
| BOILING POINT | ||
| SPECIFIC GRAVITY | ||
| SOLUBILITY IN WATER | ||
| pH | ||
| VAPOR DENSITY |
| |
|
AUTOIGNITION |
| |
|
NFPA RATINGS |
||
|
REFRACTIVE INDEX |
||
| FLASH POINT |
| |
| STABILITY | Stable under ordinary conditions. | |
|
APPLICATIONS |
||
| Milrinone, non-glycoside cardiotonic agent, is used in the short-term management of congestive heart failure unresponsive to digitalis, diuretics, or vasodilators. It is a phosphodiesterase inhibitor which prevents enzymatic breakdown of cyclic GMP with positive inotropic and vasodilator effects. Milrinone is a yellowish crystalline compound; slightly soluble in methanol; practically insoluble in chloroform and in water. Its chemical name is 1,6-Dihydro-2-methyl-6-oxo-(3,4'-bipyridine)-5- carbonitrile. The lactate salt of amrinone is administered intravenously. | ||
| SALES SPECIFICATION (USP/NF) | ||
|
APPEARANCE |
yellow crystalline powder | |
|
ASSAY |
98.5% - 101.5% | |
|
WATER |
2.0% max |
|
|
INDIVIDUAL IMPURITY |
0.2% max (TOTAL 0.5% max) |
|
|
SOLVENT RESIDUE |
0.1% max |
|
| HEAVY METALS |
20ppm max |
|
| TRANSPORTATION | ||
| PACKING |
| |
| HAZARD CLASS | 6 (Packing Group: III) | |
| UN NO. | 2811 | |
| OTHER INFORMATION | ||
| Hazard Symbols: T, Risk Phrases: 23/24/25, Safety Phrases: 36/37/39-45 | ||
|
|
|
